Arcadia Biosciences announced the immediate exercise of certain outstanding preferred investment options.
The exercise involves purchasing up to 808,595 shares at a reduced price of $2.575 per share.
The company expects gross proceeds of approximately $2.1 million from this exercise.
Gross Proceeds
Approximately $2.1 million expected from the exercise of preferred investment options.
Exclusive Placement Agent
H.C. Wainwright & Co. acts as the exclusive placement agent for the offering.
New Preferred Investment Options
Arcadia will issue new unregistered preferred investment options to purchase up to 1,617,190 shares.
- The offering is expected to close on or about January 12, 2026, subject to customary closing conditions.
- The net proceeds will be utilized by Arcadia for working capital and general corporate purposes.
Arcadia Biosciences' exercise of preferred investment options will provide a boost in capital for future operations and growth.